

06 Nov 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: Pfizer's COVID transition; Lilly ramps up Mounjaro on strong demand; Pfizer's R&D head reflects on pandemic experience; parsing Novartis's Q3; and China's progress with mRNA vaccines.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 4 November 2022, including: [Pfizer Inc.](#)'s COVID transition; [Eli Lilly and Company](#) ramps up Mounjaro on strong demand; Pfizer's R&D head reflects on pandemic experience; parsing [Novartis AG](#)'s Q3; and China's progress with mRNA vaccines.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Pfizer Plans For COVID Transition And RSV Vaccine Launch](#)" - Scrip, 1 Nov, 2022.)

(Also see "[Lilly Preparing For Increasing Mounjaro Demand On Top Of Solid Launch](#)" - Scrip, 1 Nov, 2022.)

(Also see "[Pfizer R&D Chief Mikael Dolsten Reflects On The COVID-19 Pandemic Experience](#)" - Scrip, 1 Nov, 2022.)

(Also see "[Stock Watch: Why Novartis's Q3 Misses Matter](#)" - Scrip, 1 Nov, 2022.)

(Also see "[*China mRNA COVID Vaccines Progress As Shanghai Rolls Out First Inhaled Shot*](#)" - Scrip, 28 Oct, 2022.)

[*Click here to explore this interactive content online*](#) ✎